OBJECTIVE: To determine the frequency of nuclear factor κB (NFκB) and the chemokine receptor CXCR4 co-expression in prostate cancer specimens from men with locally advanced disease. PATIENTS AND METHODS: Paraffin-embedded samples from patients enrolled on the Radiation Therapy Oncology Group (RTOG) 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. The amount of NFκB and CXCR4 was scored by a 'blinded' pathologist for the percentage of cells stained (0-100%) and staining intensity (0-3 +). Cox proportional hazard models were used for overall survival and disease-free survival to examine if NFκB and/or CXCR4 expression were associated with patient outcomes with and without adjustment for covariates. RESULTS: Available material and successful staining allowed NFκB and CXCR4 status to be determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 patients. Of these, 53% were 2/3 + for cytoplasmic NFκB staining and 56% were 2/3 + for CXCR4. In all, 18 of the 51 patients were 2/3 + for both NFκB and CXCR4 (P = 0.129). Ten of 11 patients with 3 + NFκB had 2/3 + CXCR4 (P= 0.004). In this small study, neither NFκB nor CXCR4 were associated with prostate cancer outcomes. CONCLUSIONS: High NFκB expression is associated with CXCR4 expression and they are co-expressed in about one third of patients with clinically localized prostate cancer. Larger studies to accurately determine the frequency of co-expression and prognostic utility of NFκB and CXCR4 alone and in combination are warranted.
OBJECTIVE: To determine the frequency of nuclear factor κB (NFκB) and the chemokine receptor CXCR4 co-expression in prostate cancer specimens from men with locally advanced disease. PATIENTS AND METHODS: Paraffin-embedded samples from patients enrolled on the Radiation Therapy Oncology Group (RTOG) 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. The amount of NFκB and CXCR4 was scored by a 'blinded' pathologist for the percentage of cells stained (0-100%) and staining intensity (0-3 +). Cox proportional hazard models were used for overall survival and disease-free survival to examine if NFκB and/or CXCR4 expression were associated with patient outcomes with and without adjustment for covariates. RESULTS: Available material and successful staining allowed NFκB and CXCR4 status to be determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 patients. Of these, 53% were 2/3 + for cytoplasmic NFκB staining and 56% were 2/3 + for CXCR4. In all, 18 of the 51 patients were 2/3 + for both NFκB and CXCR4 (P = 0.129). Ten of 11 patients with 3 + NFκB had 2/3 + CXCR4 (P= 0.004). In this small study, neither NFκB nor CXCR4 were associated with prostate cancer outcomes. CONCLUSIONS: High NFκB expression is associated with CXCR4 expression and they are co-expressed in about one third of patients with clinically localized prostate cancer. Larger studies to accurately determine the frequency of co-expression and prognostic utility of NFκB and CXCR4 alone and in combination are warranted.
Authors: Caren C Bancroft; Zhong Chen; Jason Yeh; John B Sunwoo; Ning T Yeh; Sadhana Jackson; Chad Jackson; Carter Van Waes Journal: Int J Cancer Date: 2002-06-01 Impact factor: 7.396
Authors: Junxia Min; Alexander Zaslavsky; Giuseppe Fedele; Sara K McLaughlin; Elizabeth E Reczek; Thomas De Raedt; Isil Guney; David E Strochlic; Laura E Macconaill; Rameen Beroukhim; Roderick T Bronson; Sandra Ryeom; William C Hahn; Massimo Loda; Karen Cichowski Journal: Nat Med Date: 2010-02-14 Impact factor: 53.440
Authors: Liying Zhang; Saleh Altuwaijri; Fangming Deng; Lishi Chen; Priti Lal; Umeshkumar K Bhanot; Ruslan Korets; Sven Wenske; Hans G Lilja; Chawnshang Chang; Howard I Scher; William L Gerald Journal: Am J Pathol Date: 2009-07-23 Impact factor: 4.307
Authors: Nicolas Barry Delongchamps; Frédéric Beuvon; Jacques R R Mathieu; Stéphanie Delmas; Isabelle Metzger; Hervé Prats; Florence Cabon Journal: World J Urol Date: 2014-04-19 Impact factor: 4.226
Authors: P T Tran; R K Hales; J Zeng; K Aziz; T Salih; R P Gajula; S Chettiar; N Gandhi; A T Wild; R Kumar; J M Herman; D Y Song; T L DeWeese Journal: Curr Mol Med Date: 2012-07-01 Impact factor: 2.222
Authors: Victoria Wang; Milan S Geybels; Kristina M Jordahl; Travis Gerke; Anis Hamid; Kathryn L Penney; Sarah C Markt; Matthew Freedman; Mark Pomerantz; Gwo-Shu M Lee; Huma Rana; Daniela Börnigen; Timothy R Rebbeck; Curtis Huttenhower; Ros A Eeles; Janet L Stanford; Practical Consortium; Sonja I Berndt; Frank Claessens; Karina D Sørensen; Jong Y Park; Ana Vega; Nawaid Usmani; Lorelei Mucci; Christopher J Sweeney Journal: Prostate Date: 2021-05-06 Impact factor: 4.012
Authors: Joo Yong Lee; Dong Hyuk Kang; Doo Yong Chung; Jong Kyou Kwon; Hyungmin Lee; Nam Hoon Cho; Young Deuk Choi; Sung Joon Hong; Kang Su Cho Journal: World J Mens Health Date: 2014-12-29 Impact factor: 5.400
Authors: Ho Cheol Shin; Jongwon Seo; Byung Woog Kang; Joon Ho Moon; Yee Soo Chae; Soo Jung Lee; Yoo Jin Lee; Seoae Han; Sang Kyung Seo; Jong Gwang Kim; Sang Kyun Sohn; Tae-In Park Journal: Korean J Intern Med Date: 2014-10-31 Impact factor: 2.884
Authors: Kang Su Cho; So Jung Yoon; Joo Yong Lee; Nam Hoon Cho; Young Deuk Choi; Yun Seob Song; Sung Joon Hong Journal: Oncol Lett Date: 2013-08-06 Impact factor: 2.967